Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Lifestyle Health and Longevity

Information Blocking in Healthcare Is Down — But a Stubborn Minority of IT Vendors Keep Doing It Routinely

by Team Lumida
July 13, 2026
in Health and Longevity
Reading Time: 4 mins read
A A
0
doctor holding red stethoscope

Photo by Online Marketing on Unsplash

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp
  • The share of health information exchange organizations reporting instances of potential information blocking dropped from more than 90% in 2019 to 71% in 2025, according to new data from the Office of the National Coordinator for Health Information Technology — a meaningful improvement over six years that the ONC attributes partly to the regulatory framework established by the 21st Century Cures Act (2016) and the information blocking rules that went into effect in 2021; however, the improvement masks a persistent hard core of bad actors: the share of exchanges routinely experiencing blocking has remained unchanged over the entire period.
  • Health IT developers — not hospitals — are the primary information blockers: more than 60% of health information exchanges said IT developers sometimes or routinely hindered health data flow in 2025, compared with about half of hospitals and health systems; approximately 60% said IT developers used fees and pricing to potentially block data sharing, down from over 80% in 2019; the pattern suggests that proprietary data lock-in remains a business model for a subset of health IT vendors despite federal prohibition.
  • The enforcement picture has been weak: the Trump administration has issued notices of nonconformity to potential information blockers, but as of March 2026 the federal government had not levied any penalties or enforcement actions despite the rules having been in effect since 2021 — National Coordinator Dr. Thomas Keane told lawmakers in March that action was coming, with IT developers facing potential loss of ONC health IT certification and fines from the HHS Office of Inspector General.
  • The ONC’s analysis carries a policy implication: since most information blocking is concentrated among a small group of repeat offenders (“fewer specific entities may be engaged in potential information blocking, and some share of those entities are consistently doing so routinely”), targeted enforcement against a small number of high-frequency blockers could have an outsized impact on overall data exchange — a precision enforcement strategy rather than broad regulatory pressure.

What Happened?

The ONC released new data showing improvement in health information blocking trends from 2019 to 2025: the share of health information exchanges reporting any potential blocking fell from over 90% to 71%. But the analysis also reveals that routine blocking by a minority of IT developers and hospitals has not declined — the same roughly one-third of exchanges that experienced routine IT developer blocking in 2019 still experienced it in 2025. The federal government has yet to levy any fines or enforcement actions despite rules that have been in effect for five years.

Why It Matters?

Information blocking is not a technical problem — it is a business model problem. Health IT vendors that have built proprietary data ecosystems have financial incentives to make it difficult for patients and providers to move data to competing systems. The 21st Century Cures Act tried to address this by prohibiting blocking and establishing a penalty regime, but five years of non-enforcement have undermined deterrence. The consequence is real: patients whose records are fragmented across systems that don’t communicate face worse care coordination, duplicate testing, and medication errors that more seamless data exchange would prevent. The concentration of blocking among IT vendors — rather than hospitals — points to the EHR and health IT industry as the primary target for enforcement action.

What’s Next?

The ONC and HHS OIG have signaled that enforcement is coming. The first actual penalty levied against an information blocker — whether an IT developer losing its ONC certification or a firm being fined by the OIG — will be the signal that the regulatory framework has teeth. Watch for whether the Trump administration’s stated commitment to information blocking enforcement materializes in specific actions against named vendors before the end of 2026. The TEFCA (Trusted Exchange Framework and Common Agreement) rollout, which the ONC is separately accelerating, provides the interoperability infrastructure that makes blocking harder and less valuable as a competitive strategy.

Source: Healthcare Dive

Previous Post

Bitcoin Sits Out the War: Crypto Holds Near $63,800 as Gold, Oil, Stocks, and Bonds All Sell Off on Fourth Iran Strike

Next Post

The Real AI Jobs Threat Isn’t Unemployment — It’s a Coming Labor Shortage That AI May Need to Fill

Recommended For You

US Alcohol Consumption Holds at Historic Low as Majority of Americans Now Say Drinking Is Bad for Health

by Team Lumida
2 days ago
clear drinking glass with ice cubes

A Gallup poll of 1,200 adults finds 54% of Americans consume alcohol — matching last year's historic low and halting three consecutive annual declines — while 51% now...

Read more

Big Food’s GLP-1 Reckoning: Conagra, Kraft, and Packaged-Food Giants Reformulate for the Not-So-Hungry

by Team Lumida
3 days ago
pasta with red sauce on white ceramic round plate

As GLP-1 weight-loss drugs suppress appetite across millions of households, packaged-food companies are retooling recipes, portion sizes, and sensory profiles to win over consumers who eat less but...

Read more

Novo Nordisk Tests Low-Dose Wegovy Pills as Most Patients Already Stick to Smallest Doses

by Team Lumida
3 days ago
Novo Nordisk Q2 2024 Earnings Highlights

Novo Nordisk has launched a 450-person trial to determine the minimum effective dose of its oral Wegovy pill — a clinically significant shift given that more than two-thirds...

Read more

4 in 5 Americans Say Healthcare Costs Are the Nation’s Top Health Problem — and Nobody Agrees on Who Should Fix It

by Team Lumida
4 days ago
doctor holding red stethoscope

A Commonwealth Fund survey of 25,873 adults finds near-universal alarm over health insurance premiums and out-of-pocket costs, even as ACA marketplace premiums surge 58% in 2026 and nearly...

Read more

Wealthy, Healthy, and Ready to Spend: Baby Boomers Are Driving a Global Travel Boom the Industry Is Racing to Serve

by Team Lumida
5 days ago
couple kissing on the road during daytime

Baby boomers — flush with retirement savings and in better health than previous generations — are fueling a high-end travel surge, with the industry responding with private-plane tours,...

Read more

385 Million Patient Records Breached and Counting — DentaQuest’s 15M-Person Hack Leads a New Wave of Healthcare Cybersecurity Disasters

by Team Lumida
1 week ago
person sitting while using laptop computer and green stethoscope near

The updated Healthcare Dive breach tracker reveals a sector in crisis: DentaQuest's 15M breach in 2026, Conduent's 62M in 2025, and Change Healthcare's record 192.7M in 2024.

Read more

Healthcare Stocks Are Now an Implicit AI Short — Semiconductors and Pharma Have Flipped to Negative Correlation

by Team Lumida
2 weeks ago
turned on monitoring screen

A structural shift is underway in equity markets: the VanEck Semiconductor ETF and the State Street Health Care ETF have moved into negative correlation, meaning healthcare has effectively...

Read more

Patients Are Using AI to Interpret Their Medical Test Results Before Seeing Doctors — And Doctors Are Struggling to Untangle the Errors

by Team Lumida
2 weeks ago
doctor holding red stethoscope

Roughly a third of American adults now consult AI for health advice, and the majority view test results online before speaking with a doctor — a trend accelerated...

Read more

Novo Nordisk’s $10 Billion Cardiovascular Bet Fails — Ziltivekimab Misses Heart Attack and Stroke Endpoint, Stock Drops 10.5%

by Team Lumida
3 weeks ago
Novo Nordisk Q2 2024 Earnings Highlights

Novo Nordisk's experimental drug ziltivekimab — a monthly IL-6 inhibitor injection targeting cardiovascular disease, chronic kidney disease, and inflammation in a market Jefferies estimates at $10B+ annually —...

Read more

Trump Administration to End $3.6 Billion Medicare Drug Premium Subsidy — Seniors Face Higher Part D Costs in 2027

by Team Lumida
3 weeks ago
Supreme Court Signals It Will Strike Down Trump’s Birthright Citizenship Order

The Trump administration will not renew the Part D Low Income Premium Subsidy program after 2026, eliminating $3.6 billion in annual payments to insurers that have been holding...

Read more
Next Post
AI Investment Boom: How Tech Giants Are Leading the Charge

The Real AI Jobs Threat Isn't Unemployment — It's a Coming Labor Shortage That AI May Need to Fill

Nvidia CEO Reveals Secrets Behind AI Domination Amidst Fierce Competition

Wall Street to AI Hyperscalers: Slow Down — $75B From Nvidia, SpaceX, and Amazon Is Testing the Bond Market's Limits

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

Nvidia Defies US Controls: $12 Billion AI Chip Sales in China

Nvidia CEO Meets Trump Amid AI Leadership Concerns and Tariff Threats

February 1, 2025
Asia’s IPO Boom: India and Japan Surge Past China

Asia’s IPO Boom: India and Japan Surge Past China

October 14, 2024
September Rate Cut Likely as Job Market Risks Increase, Says Fed

Fed Moves to Quash DOJ Subpoenas in Powell Probe, Escalating Independence Standoff

February 27, 2026

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto data centers Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Intel Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018